Q4 2021 Cantargia AB Earnings Call Transcript
¶ -
Thank you so much. It's a pleasure to present the new full-year report for Cantargia. And if we go through the slides here and go down to slide number 4, I can conclude that Cantargia evolved quite a lot during 2021, with several important milestones that we reached. And during the fourth quarter, we presented a very strong period with a very significant amount of news.
And as you can see here, it relates to new clinical data. It relates to regulatory status in Europe in pancreatic cancer. It relates to clinical trials starting with first patients in. And what's also clear is that we made a very, very important step forward in our development in pancreatic cancer by signing an agreement with the US organization PanCAN and participation in their Precision Promise Phase 3 trial.
We also had some news on the patent side, which we will spend a little bit time on because I think it's, I [guess], (technical difficulty) [patients] around it, and we'd like to highlight exactly what all these patients are about. We also made progress in the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
